"Morpholines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D009025
|
| MeSH Number(s) |
D03.383.533.640
|
| Concept/Terms |
Morpholines- Morpholines
- Tetrahydro-1,4-Oxazines
- Tetrahydro 1,4 Oxazines
|
Below are MeSH descriptors whose meaning is more general than "Morpholines".
Below are MeSH descriptors whose meaning is more specific than "Morpholines".
This graph shows the total number of publications written about "Morpholines" by people in this website by year, and whether "Morpholines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2008 | 1 | 3 | 4 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Morpholines" by people in Profiles.
-
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 2022 03 17; 386(11):1034-1045.
-
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
-
Systemic hypersensitivity to fosaprepitant - A report of two cases. J Oncol Pharm Pract. 2018 Jan; 24(1):76-78.
-
Differences in the Control of Secondary Peristalsis in the Human Esophagus: Influence of the 5-HT4 Receptor versus the TRPV1 Receptor. PLoS One. 2016; 11(7):e0159452.
-
Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat Rev Cardiol. 2014 Dec; 11(12):693-703.
-
Rivaroxaban for treatment of venous thromboembolism in older adults. Consult Pharm. 2014 Sep; 29(9):627-30.
-
Effects of mosapride on secondary peristalsis in patients with ineffective esophageal motility. Scand J Gastroenterol. 2013 Dec; 48(12):1363-70.
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 04 05; 366(14):1287-97.
-
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Mol Cancer Ther. 2011 Jul; 10(7):1137-48.
-
Effects of mosapride on esophageal secondary peristalsis in humans. Neurogastroenterol Motil. 2011 Jul; 23(7):606-e249.